Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemotherapy and terminal skeletal muscle differentiation in WT1-mutant Wilms tumors.

Cancer medicine - 1 Apr 2018

Royer-Pokora Brigitte, Beier Manfred, Brandt Artur, Duhme Constanze, Busch Maike, de Torres Carmen, Royer Hans-Dieter, Mora Jaume

Abstract excerpt

Wilms tumors (WT) with WT1 mutations do not respond well to preoperative chemotherapy by volume reduction, suggesting resistance to chemotherapy. The histologic pattern of this tumor subtype indicates an intrinsic mesenchymal differentiation potential. Currently, it is unknown whether cytotoxic treatments can induce a terminal differentiation state as a direct comparison of untreated and chemotherapy-treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Muscle Development

Share to Muscle, Skeletal

Share to Reelin Protein

Share to Wilms Tumor

Share to WT1 Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 29542868
DOI: 10.1002/cam4.1379
PMCID: PMC5911586

Genes

CTNNB1
MYF6
RELN
TBX2
TBX4
TBX5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemotherapy and terminal skeletal muscle differentiation in WT1-mutant Wilms tumors.PMID 29542868Read ↗

Two molecular subgroups of Wilms' tumors with or without WT1 mutations.Semantic proximity Read ↗

Wilms' tumor gene 1 in hematological malignancies: friend or foe?Semantic proximity Read ↗

Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 MutationsSemantic proximity Read ↗

Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcomaSemantic proximity Read ↗

Transcriptomic profiling of recurrent Rhabdomyosarcoma: Pre- and post-treatment tissue analysis reveals molecular characteristics of acquired resistance.Semantic proximity Read ↗

CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.Semantic proximity Read ↗

Transcriptomic analyses of MYCN-regulated genes in anaplastic Wilms’ tumour cell lines reveals oncogenic pathways and potential therapeutic vulnerabilitiesSemantic proximity Read ↗

Upregulation of HOXA3 by isoform‐specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemiaSemantic proximity Read ↗

Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.Semantic proximity Read ↗

Wilms' tumor 1 expression combined with genetic mutations for prognostic assessment in MDS.Semantic proximity Read ↗

Characterization of primary Wilms tumor cultures as an in vitro model.Semantic proximity Read ↗

SIX1 Reprograms Myogenic Transcription Factors to Maintain the Rhabdomyosarcoma undifferentiated stateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.